Compare Lionsgate Studios Corp Common Shares (LION) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lionsgate Studios Corp Common Shares vs Medtronic PLC — how do they compare? Lionsgate Studios Corp Common Shares trades at $10.89 (market cap $3.24B), while Medtronic PLC trades at $95 (market cap $120.53B). The key difference: Medtronic PLC is far larger — about 37.2× Lionsgate Studios Corp Common Shares's market cap, and Medtronic PLC pays a 3.06% dividend while Lionsgate Studios Corp Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lionsgate Studios Corp Common Shares for 0 Days and Medtronic PLC for 63 Days on average.
| LION | MDT | |
|---|---|---|
Market Cap | $3.24B | $120.53B |
Volume | 3,214,595 | 49,858,758 |
Sector | Technology | Health |
52-Week High | $16.40 | $105.35 |
52-Week Low | $5.91 | $73.75 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $6.75B | $139.87B |
Dividend Yield | — | 3.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
Medtronic (MDT) trades at $93.01, up 1.17% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats, 7% revenue growth in Q1 2026, and a 49-year dividend growth streak. Valuation metrics include a P/E of 22.91 and P/S of 3.19. Recent positive news includes FDA clearances for medical devices and raised full-year guidance, supporting investor confidence.
Outlook remains positive with analyst consensus at Buy (61%) and $97.73 price target. Key opportunities include sustained dividend growth and new product approvals, while risks involve debt increase to 31.11% of assets and competitive pressures. The stock's current level near resistance at $93 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lionsgate Studios Corp Common Shares
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
